Navigation Links
Cellzome Announces Second Major Strategic Drug Discovery Alliance with GlaxoSmithKline in Inflammatory Disease
Date:3/10/2010

Collaboration Exploits Cellzome's World-Leading Proteomics Technology in Epigenetics

CAMBRIDGE, England and HEIDELBERG, Germany, March 10, 2010 /PRNewswire/ -- Cellzome today announced that it has formed a second strategic alliance with GlaxoSmithKline (GSK). This new collaboration gives GSK exclusive access to Cellzome's proprietary Episphere(TM) technology in the emerging field of epigenetics as applied to immunoinflammatory disease. Epigenetic mechanisms play a key role in controlling immune cell differentiation and inflammatory gene expression during an excessive inflammatory response.

Under the terms of the agreement, the companies will work together using Cellzome's Episphere(TM) technology platform, to identify selective small-molecule drug candidates against targets from four different epigenetic target classes. The companies will share operational responsibility for the programs until identification of drug candidates, at which stage GSK will assume responsibility for any further preclinical and clinical development and commercialisation.

Under the financial terms, Cellzome will receive an upfront payment of EUR33 million, comprising technology access fees and the purchase of equity. In addition, Cellzome is eligible for milestone payments and tiered royalties for each programme. Milestone payments under this collaboration could reach over EUR475 million if all programmes under the alliance are successfully developed and commercialised.

Tim Edwards, Chief Executive Officer of Cellzome, said: "We are delighted to form another major alliance with GSK, using our leading technology and people to find transformative medicines in this exciting field of biology. Combining forces with GSK will accelerate the development of new anti-inflammatory drugs for the benefit of patients."

About Cellzome

Cellzome is a privately-owned drug discovery and development company, and a leader in the use of chemical proteomics technologies to identify a new generation of drug candidates for the treatment of inflammatory diseases.

Our pipeline of small-molecule therapeutics is driven by Kinobeads(TM), a proprietary technology for screening and profiling kinases in their physiological context. We have developed a new technology, called Episphere(TM) to address epigenetic targets in disease-specific protein complexes. Our goal is to identify oral therapeutics for inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

In addition to the alliance with GSK in the field of epigenetics, Cellzome has another strategic alliance with GSK to discover, develop and market kinase-targeted therapeutics to treat inflammatory disease and an alliance with Johnson & Johnson focused on the discovery of novel medicines for the treatment of Alzheimer's disease.

Cellzome's holding company is domiciled in the US and it employs about 90 people at its two R&D laboratories in Cambridge, UK and Heidelberg, Germany. To learn more about Cellzome, please visit the website: http://www.cellzome.com.

About Episphere(TM) and epigenetics

Episphere(TM) is a chemical proteomics technology for the discovery of novel drugs directed against targets involved in epigenetic regulation. The technology allows the screening and profiling of inhibitors of epigenetic targets in their native environment, directly in the lysate of cells and tissues and can also differentiate between the complexes these targets operate in. The term epigenetics refers to heritable changes in gene expression and phenotype caused by mechanisms other than changes in DNA sequence. One major mechanism is the specific enzymatic modification of histone tails, which affects the packaging of DNA into chromatin and through that controls the transcription of specific genes. Enzymes, such as histone deacetylases (HDAC) or methyltransferases (HMT) can change the modification of the histone tails and therefore change the 'histone code'. Dysregulation of these modifications is thought to play a central role in cancer and in chronic degenerative diseases like neurological and autoimmune disease. The enzymes which carry out these histone modifications are part of large multifunctional protein complexes, which represent attractive novel targets for drug discovery.

SOURCE Cellzome

Back to top
'/>"/>
SOURCE Cellzome
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. InterMune Announces Conference Call and Webcast to Discuss Outcome of FDA Advisory Committee
2. Micromet Announces Proposed Public Offering of Common Stock
3. Orthopaedic Synergy, Inc. Announces Letter of Intent to Acquire Praxim, SA.
4. MiMedx Group Announces Addition of Sales Director for Europe
5. Arbor Pharmaceuticals Announces the Launch of Pediaderm(TM) HC Complete Kit - A Comprehensive Approach to the Management of Atopic Dermatitis
6. Orexigen(R) Therapeutics Announces Fourth Quarter and Year Ended December 31, 2009 Financial Results
7. INSYS Therapeutics, Inc. Announces Positive Phase III Efficacy Trial Results for Fentanyl Sublingual Spray
8. Genomic Health Announces Publication of Study Using Oncotype DX(R) in Node-Negative and Node-Positive Breast Cancer Patients Treated With Aromatase Inhibitors
9. BioSpecifics Technologies Corp. Announces Availability of XIAFLEX(TM) for the Treatment of Dupuytrens Contracture
10. Microfluidics Announces Two New Board Members
11. Lexicon Announces Proposed $95 Million Common Stock Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... 2016 Research and Markets has announced ... report to their offering. ... a favourable commercial environment for MedImmune to enter. The US ... will serve to drive considerable growth for effective anti-influenza medications. ... cap sales considerably, but development is still in its infancy. ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
(Date:6/23/2016)...  Guerbet announced today that it has been named ... . One of 12 suppliers to receive ... support of Premier members through exceptional local customer service ... to lower costs. ... outstanding customer service from Premier," says Massimo Carrara ...
Breaking Medicine Technology:
(Date:6/26/2016)... ... ... Quality metrics are proliferating in cancer care, and are derived from many ... the beholder, according to experts who offered insights and commentary in the current issue ... the full issue, click here . , For the American Society of Clinical ...
(Date:6/26/2016)... ... June 26, 2016 , ... PawPaws brand pet ... product that was developed to enhance the health of felines. The formula is all-natural ... two main herbs in the PawPaws Cat Kidney Support Supplement Soft Chews ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX ... Austin - CEO of Pixel Film Studios. , ProHand Cartoon’s package transforms over ... Cut Pro X . Simply select a ProHand generator and drag it above media ...
(Date:6/25/2016)... Oklahoma (PRWEB) , ... June 25, 2016 , ... ... both athletes and non-athletes recover from injury. Recently, he has implemented orthobiologic procedures ... Oklahoma City area —Johnson is one of the first doctors to perform the ...
Breaking Medicine News(10 mins):